Humacyte, Inc. (NASDAQ:HUMA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Humacyte, Inc. (NASDAQ:HUMA) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 775,718 shares of the company’s stock after acquiring an additional 54,400 shares during the period. Charles Schwab Investment Management Inc. owned about 0.62% of Humacyte worth $3,917,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new stake in shares of Humacyte during the fourth quarter worth about $50,000. Brookstone Capital Management acquired a new stake in Humacyte during the 4th quarter worth approximately $56,000. ACT Wealth Management LLC purchased a new position in Humacyte in the 4th quarter valued at approximately $57,000. FORA Capital LLC acquired a new position in shares of Humacyte in the third quarter worth $96,000. Finally, Insigneo Advisory Services LLC purchased a new stake in shares of Humacyte during the third quarter worth $109,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Performance

NASDAQ:HUMA opened at $2.00 on Thursday. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $9.97. The stock has a market cap of $251.72 million, a P/E ratio of -1.49 and a beta of 1.36. The stock has a 50-day simple moving average of $3.71 and a 200-day simple moving average of $4.55.

Analysts Set New Price Targets

HUMA has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.